Piper Sandler analyst Adam Maeder raised the firm’s price target on ResMed (RMD) to $270 from $248 and keeps a Neutral rating on the shares. The firm notes the company reported Q4 results that beat estimates on the top-line and bottom-line. Altogether, Piper views this as a solid quarterly update from ResMed led by the gross margin performance with U.S. devices the one soft spot. However, the firm elects to stay on the sidelines for the time being.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD: